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Abstract objective Since the 1980s, dengue incidence has increased 30-fold. However, in 2017, there was a
noticeable reduction in reported dengue incidence cases within the Americas, including severe and
fatal cases. Understanding the mechanism underlying dengue’s incidence and decline in the Americas
is vital for public health planning. We aimed to provide plausible explanations for the decline in
2017.
methods An expert panel of representatives from scientific and academic institutions, Ministry of
Health officials from Latin America and PAHO/WHO staff met in October 2017 to propose
hypotheses. The meeting employed six moderated plenary discussions in which participants reviewed
epidemiological evidence, suggested explanatory hypotheses, offered their expert opinions on each
and developed a consensus.
results The expert group established that in 2017, there was a generalised decreased incidence,
severity and number of deaths due to dengue in the Americas, accompanied by a reduction in
reported cases of both Zika and chikungunya virus infections, with no change in distribution among
age groups affected. This decline was determined to be unlikely due to changes in epidemiological
surveillance systems, as similar designs of surveillance systems exist across the region. Although
sudden surveillance disruption is possible at a country or regional level, it is unlikely to occur in all
countries simultaneously. Retrospective modelling with epidemiological, immunological and
entomological information is needed. Host or immunological factors may have influenced the decline
in dengue cases at the population level through immunity; however, herd protection requires
additional evidence. Uncertainty remains regarding the effect on the outcome of sequential infections
of different dengue virus (DENV) types and Zika virus (ZIKV), and vice versa. Future studies were
recommended that examine the epidemiological effect of prior DENV infection on Zika incidence
and severity, the epidemiological effect of prior Zika virus infection on dengue incidence and severity,
immune correlates based on new-generation ELISA assays, and impact of prior DENV/other
arbovirus infection on ZIKV immune response in relation to number of infections and the duration of
antibodies in relation to interval of protection. Follow-up studies should also investigate whether
increased vector control intensification activities contributed to the decline in transmission of one or
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more of these arboviruses. Additionally, proposed studies should focus on the potential role of vector
competence when simultaneously exposed to various arboviruses, and on entomological surveillance
and its impact on circulating vector species, with a goal of applying specific measures that mitigate
seasonal occurrence or outbreaks.
conclusions Multifactorial events may have accounted for the decline in dengue seen in 2017.
Differing elements might explain the reduction in dengue including elements of immunity, increased
vector control, and even vector and\or viruses changes or adaptations. Most of the results of this
expert consensus group meeting are hypothetical and based on limited evidence. Further studies are
needed.
keywords Dengue, decline, Americas, hypotheses
Introduction
Dengue virus (DENV) infections are a major interna-
tional public health concern. During the past 40 years,
the global incidence of dengue has increased 30-fold [1].
Up to 100 million new infections are estimated to occur
annually in tropical and subtropical areas of the world
[2], with documented further spread to previously unaf-
fected areas [3]. Dengue can be caused by any of the four
DENV serotypes (DENV 1 to 4), an RNA virus of
the Flaviviridae family. Aedes mosquitoes, primarily
Aedes aegypti and Aedes albopictus, transmit the disease.
Dengue infection can result in a broad spectrum of symp-
toms, ranging from asymptomatic infections to a self-lim-
ited illness to severe dengue and potentially lethal
outcomes. Without rapid clinical diagnosis and appropri-
ate therapy, severe dengue case fatality rates can exceed
20% [2]. The economic impact of dengue in the Ameri-
cas is estimated at $2.1 billion (USD) per year on average
[4].
Between the 1950s and 1960s, the Americas were a vir-
tually dengue-free zone due to a continental Aedes
aegypti eradication campaign supported and led by the
Pan American Health Organization (PAHO), that began
in 1947 [5, 6]. Unfortunately, after the campaign’s end in
the 1960s, vector control efforts were not maintained.
This, along with the rapid population growth and accel-
eration of uncontrolled urbanisation in Latin America,
contributed to the re-infestation with Aedes aegypti and
the return of DENV circulation [7]. During the early and
mid-1970s, outbreaks associated with DENV-2 were
reported in Colombia and in the Caribbean, and until
1977, DENV-2 and DENV-3 serotypes continued to cir-
culate in the region. By 1978, DENV-1 had spread to
South America, Central America, and Mexico. Overall,
the countries in the Americas reported approximately
702 000 cases during 1977–1980, with DENV-1 being
the predominant serotype [8, 9].
During the 1980s and early 1990s, reported dengue
incidence was relatively stable, apart from 1981 when
Cuba reported over 340 000 cases caused by DENV-2.
However, since the 1990s, the Americas have experienced
sharp increases in dengue case numbers. The region
reported over 4.7 million dengue cases from 2000 to
2007 vs. 3.76 million cases during 1980–1999 [10]. The
increasing trend within the Region has continued in
recent years, with reported dengue cases rising nearly
three-fold from 857 534 cases in 2008 to 2.3 million dur-
ing 2016 [11] (in 2016, cases of Zika could have been
misclassified as dengue). The year 2016 was characterised
by large dengue outbreaks with Brazil alone contributing
slightly less than 1.5 million cases, approximately three
times more than in 2014. The region also reported 1032
dengue-related deaths [11].
The introduction of chikungunya virus (CHIKV) and
Zika virus (ZIKV) in 2013 and 2015, respectively, has cre-
ated new public health challenges. The similarity of symp-
toms between the three viral diseases hindered accurate
clinical diagnosis and appropriate patient treatment by
healthcare providers (at least initially). Serological diagno-
sis is difficult due to cross-reaction between IgM and IgG
antibodies against ZIKV and DENV, which complicates
laboratory confirmation and case reporting. More than
534 000 Zika and 351 000 chikungunya cases were
reported during 2016 [12, 13]. Yet, despite the recent
emergence of these two viruses, dengue remains the most
common mosquito-borne disease in the Americas.
In 2017, however, there was a noticeable reduction in
dengue incidence in the Americas (Figure 1). In compar-
ison to the 2 177 118 cases reported during 2016, total
dengue virus cases reported in the region during 2017 fell
by 73% [11]; by a total of 584 263 reported cases. This
was the lowest case number since 2006, when 537 412
cases were reported. Moreover, the number of severe and
fatal dengue cases during 2017 was the lowest since the
Region’s Integrated Management Strategy for dengue
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prevention and control in the Americas (IMS-Dengue)
was implemented in 2003 (Table 1 and Figure 2). Aruba,
Panama and Peru are the only countries in the Americas
that observed increases in dengue cases in 2017 vs. 2016
[11] (Tables 2, 3).
Understanding the mechanism(s) underlying the decline
in reported dengue incidence in the Americas is key for
public health planning. Questions arising from this obser-
vation need to be answered to better guide future dengue
programmatic actions and outbreak management and con-
trol. It is currently unknown whether vector control mea-
sures reduced the magnitude of the epidemic, and if so,
when such measures should be initiated in future to reduce
the risk of large dengue outbreaks developing. The aim of
the present discussion and analysis was to hypothesise and
present some plausible explanations for this decline.
Methods
A group of dengue experts convened at the PAHO
headquarters in Washington D.C., USA from October
3–5, 2017. This meeting brought together representa-
tives from scientific and academic institutions, Ministry
of Health officials from Latin America, and PAHO
staff to build a common understanding of the issue, as
well as to identify, discuss and address proposed
hypotheses. A draft hypothesis was generated by a core
group of experts from PAHO based on evidence from
the literature search. We used the nominal group tech-
nique (known as the expert panel) to gather informa-
tion from relevant experts and determine the extent to
which they agreed on a given topic [14]. A purposive
sampling method was used to recruit the experts in the
field of virology, epidemiology, clinical science, ento-
mology and laboratory for this study. They were identi-
fied based on diversity of expertise and affiliations.
Participation was voluntary. All experts were asked for
informed consent to use the information provided and
be included as co-authors of the study. After each
panel discussion, feedback was processed and sum-
marised within the expert group. The meeting
employed moderated plenary discussions. Deliberations
took place in a total of six sessions of panel discus-
sions in which the discussants offered their expert opin-
ions. The meeting’s objective was to analyse the
virological, epidemiological, and entomological factors
that could be linked with the decline in dengue cases
throughout the Americas in 2017. The data were the-
matically analysed to identify all important themes
mentioned by the experts. No non-main stream opin-
ions were identified in the discussions. Several hypothe-
ses were proposed to explain the reduction in
incidence, and with each, specific questions were thor-
oughly addressed and discussed:
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Figure 1 Dengue epidemiological situation in the Americas, 1980–2017. Source: Regional PAHO/WHO Dengue Program. 2017
updated to SE # 36. [Colour figure can be viewed at wileyonlinelibrary.com]
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Hypothesis 1: Changes in epidemiological surveil-
lance systems.
1 What were the trends in the notification of dengue,
chikungunya and Zika cases?
a Were there any changes in time, geographic location
and age-group distribution?
2 Were there any changes (e.g. case definition, surveil-
lance sites) in epidemiological surveillance systems?
Hypothesis 2: Temporary or lasting cross-immunity
generated by the simultaneous circulation of several
arboviruses.
1 Do host or immunological factors exist that may have
an influence at the population level; that is, does
immunity or herd protection play a role in the decline
in cases?
a If these effects exist, what is the expected duration?
Hypothesis 3: Changes in the density and competen-
cies of vectors.
1 Do climatic factors or changes in vector control prac-
tices exist that could have influenced or diminished the
vector population density in recent years?
2 How does the simultaneous circulation of various arbo-
viruses and vectors impact vector competence and
human transmission?
PAHO staff taped all meetings. Recordings were tran-
scribed verbatim, translated into English, and analysed
and edited for common themes.
Results
Hypothesis 1: Changes in epidemiological surveillance
systems
Ministry of Health representatives from Brazil, Colombia,
Nicaragua, Panama and Venezuela delivered presenta-
tions addressing Hypothesis 1. A summary of these pre-
sentations follows.
Countries generally reported large declines in dengue
incidence during 2017 vs. previous years. Brazil, Colom-
bia and Venezuela have all experienced considerable
declines in dengue incidence. Between 2016 and 2017,
the number of dengue cases in Brazil dropped from
1 500 535 to 252 054 Between 2016 and 2017, total
number of dengue cases in Colombia declined from
103 822 to 26 279 (75% reduction). In Venezuela,
although dengue is the most common mosquito-borne
viral illness, disease frequency was well below the mini-
mum expected levels with approximately 8600 dengue
cases reported during 2017, which is a 70% decline from
the previous year, when 29 268 dengue cases were
reported. Similarly, dengue incidence also fell in Nicara-
gua over the same period, albeit by a smaller magnitude
(27% decrease in cases). Dengue cases in Panama also
steadily declined since 2014, yet approximately 1300
more cases were reported in 2017 than in the previous
year. These declines have occurred despite high vector
presence measured in countries such as Colombia and
Panama. The expert group agreed that correspondingly,
reductions in severe or fatal dengue have also been
observed in areas in the region.
In 2017, various DENV serotypes were circulating
throughout the region. DENV-1 circulated in Brazil and
Table 1 Percentage change of total number of deaths due to
dengue reported in 2017 compared to 2016, by country and
subregion
Country/
Subregion
Epidemiological
week 2016 2017
Percentage
change
Central America
Isthmus
and Mexico
52 64 62 3%
Belize 52 0 0 0%
Costa Rica 52 0 0 0%
El Salvador 52 1 0 100%
Guatemala 52 1 24 2300%
Honduras 52 3 0 100%
Mexico 52 34 34 0%
Nicaragua 52 16 2 88%
Panama 51 9 2 78%
Andean
subregion
52 142 113 20%
Bolivia 52 2 2 0%
Colombia 52 60 15 75%
Ecuador 52 4 4 0%
Peru 52 37 76 105%
Venezuela 52 39 16 59%
Southern Cone
subregion
52 668 133 80%
Argentina 52 10 0 100%
Brazil 52 642 133 79%
Paraguay 52 16 0 100%
Latin Caribbean
subregion
52 39 3 92%
Cuba 52 0 0 0%
Dominican
Republic
52 39 3 92%
Puerto Rico 52 0 0 0%
Non-Latin
Caribbean
subregion
52 0 0 0%
The AMERICAS 52 913 311 66%
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Panama; however, Panama also reported concurrent cir-
culation of DENV-2. In 2013 and 2014, DENV 1, 2 and
3 were all co-circulating in Nicaragua, with a shift from
DENV-1 to DENV-2 as the primary serotype. DENV-2
has since been responsible for most cases. DENV-2 and
DENV-3 have been the primary DENV serotypes circu-
lating in Colombia since 2015, with DENV-3 more pre-
dominant during 2017.
The expert group agreed that the region also experi-
enced large declines in chikungunya and Zika disease
incidence in 2017. Brazil observed declines between
81% and 97% in Zika virus incidence for all five
regions (North, Northeast, Southeast, South and Mid-
west). In contrast, chikungunya incidence rose sharply
in 2017 in both the Brazilian North (129% increase)
and Midwest (89% increase). In Colombia, approxi-
mately 2000 Zika cases were reported in 2017, vs.
82 059 one year earlier, representing a 98% decline.
Chikungunya and Zika epidemics peaked in Nicaragua
during 2015 and 2016, respectively, with a subsequent
diminishment of cases [15, 16]. Chikungunya emerged
in Panama during April 2014, of which most cases were
travel-acquired. As of epidemiological week 43 (2017),
Panama continued to experience autochthonous trans-
mission of chikungunya, with 58 cases reported.
Between 2015 and 2017, Panama reported 1266 Zika
cases. Although more cases occurred in 2016, cases were
more frequent between epidemiological weeks 24–32 of
2017 than in the previous year. Zika was still occurring
in 2017 in some regions, including Panama City and
Herrera. Incidence of chikungunya and Zika in Vene-
zuela were also well below 2016 levels. Frequency of
cases for both diseases declined 98% since their epi-
demic peaks.
Based on the epidemiological surveillance data anal-
ysed, the expert group in consensus decided that the
decline in dengue incidence was unlikely due to surveil-
lance system changes for several reasons including:
• Similar design of surveillance systems within the
region operating at a country level.
• Sudden disruption of the system is possible at a coun-
try or state/regional level but unlikely to occur simul-
taneously in all countries.
• There is no evidence of significant changes that have
occurred in any of the surveillance systems in coun-
tries of the Americas, that would explain a decrease in
reporting similar to what has been observed.
Epidemiological studies have also shown that dengue
can produce endemic and epidemic cycles. A reduction
in the number of cases is typically expected after large
outbreaks due to low transmission. New outbreaks gen-
erally occur every 3–5 years due to changes in herd
immunity. The expert group established that in 2017, a
generalised decrease in the incidence, severity and num-
ber of deaths of dengue occurred in the Americas,
accompanied by a reduction in both Zika and chikun-
gunya. Despite this decline, affected age groups gener-
ally remain unchanged.
Although high incidences of dengue were reported in
2015 and 2016, the numbers should be interpreted
with some caution. The expert group concluded that
levels of over-reporting might have transpired during
this period because of initial unnoticed chikungunya
and Zika virus’s arrival to the Region, resulting in
numerous cases possibly misclassified as dengue due to
antibody test cross-reactivity. Surveillance systems in
place through each epidemic’s introduction were
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prepared to notify primarily dengue. Thus, countries in
the region had no established report form and health
care workers were not properly trained to correctly
report these new diseases, particularly during their
emergence. A major challenge for an epidemiological
surveillance system when multiple viruses are circulating
simultaneously is the initial case detection during an
epidemic.
When an arboviral epidemic begins, there is a cover-up
of the emerging disease in favour of dengue. However,
the proportion of cases misclassified is unknown. Assum-
ing that 20–40% of Zika or chikungunya cases were mis-
classified as dengue in 2015 and 2016, the decline in
dengue would not have been as abrupt in 2017. There-
fore, the group agreed that part of the decline in dengue
incidence during 2017 resulted from over-reporting
between 2015 and 2016. It was recommended that inter-
ventions modifying surveillance systems be carried out to
account for this adjustment. Therefore, hypothesis 1 was
discarded by the expert group as being the reason for the
decline in dengue cases at this time, that is, a postulation
that a change in the surveillance systems caused a reduc-
tion in dengue incidence was neither sufficient nor
demonstrated.
Hypothesis 2: Temporary or lasting cross-immunity
generated by the simultaneous circulation of several
arboviruses
Addressing Hypothesis 2 began with a review of scientific
evidence by the expert group pertaining to the existence
and duration of cross-immunity between dengue viruses
Table 2 Number of cases of dengue and Zika, and percentage change of total number of dengue cases reported in 2017 compared to
2016, by country and subregion
Country/Subregion
Epidemiological
week
Zika
cases 2016
Dengue
cases 2016
Dengue
cases 2017
Percentage
change (%)
North America subregion 52 217 990 348 65
United States of America 52 217 990 348 65
Central America Isthmus and Mexico 52 68 376 295 042 186 088 37
Belize 52 824 4713 2966 37
Costa Rica 52 6835 23 319 5561 76
El Salvador 52 11 485 8789 4300 51
Guatemala 52 4131 8844 4214 52
Honduras 52 32 234 22 961 5217 77
Mexico 52 7475 130 069 89 893 31
Nicaragua 52 2053 88 463 64 712 27
Panama 51 3339 7278 9225 27
Andean subregion 52 174 577 210 864 132 312 37
Bolivia 52 897 31 756 9938 69
Colombia 52 106 552 103 822 26 279 75
Ecuador 52 3555 14 150 11 387 20
Peru 52 1958 31 868 76 093 139
Venezuela 52 61 615 29 268 8615 71
Southern Cone subregion 52 323 782 1 651 575 258 064 84
Argentina 52 1847 79 455 557 99
Brazil 52 321 366 1 500 535 255 665 83
Paraguay 52 569 70 215 1832 97
Latin Caribbean subregion 52 41 570 8685 2617 70
Cuba 52 3 1836 1248 32
Dominican Republic 52 5241 6645 1359 80
Puerto Rico 52 36 326 204 10 95
Non-Latin Caribbean subregion 52 106 114 10 025 4834 52
Anguilla 52 42 50 22 56
Antigua and Barbuda 52 479 103 1 99
Aruba 52 704 1319 1734 31
Bahamas 52 22 82 14 83
Barbados 52 745 1433 538 62
Bermuda 52 0 2 0 100
Jamaica 52 7238 2269 70 97
The Americas 52 714 636 2 177 181 584 263 73
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and other flaviviruses. Prior DENV infection reduced risk
of symptomatic ZIKV infection in a cohort study in
Nicaragua [16]. Several studies suggest greater antibody
responses to DENV and other arboviruses after ZIKV
infections. For example, in one study recent ZIKV infec-
tions in DENV-immune individuals elicited stronger neu-
tralising DENV antibody responses for up to 6 months
than in DENV-na€ıve persons [17], but no data are avail-
able on the durability of these responses beyond
6 months. A recent study postulates that the 2015 out-
break of Zika in Brazil might have inhibited transmission
of DENV or of symptomatic infection and that ZIKV
infections could induce cross-protective immunity against
dengue virus [18]. Moreover, strong neutralising antibody
responses to ZIKV infection were observed regardless of
prior DENV exposure. ZIKV monoclonal antibody
(mAbs) studies found that in DENV-immune persons,
ZIKV neutralising antibodies are ZIKV-specific and come
from naive B cells. In contrast, DENV-cross reactive
mAbs were derived from memory B cells [19].
Other studies suggest that neutralising antibodies
(NAbs) against DENV can provide protection against
symptomatic infection. Katzelnick et al. [20] demon-
strated that pre-infection cross-reactive dengue NAbs
titres correlated with a lower risk of symptomatic sec-
ondary infection in a longitudinal pediatric dengue cohort
in Nicaragua. The protective effect remained significant
after controlling for age, and number of years between
infections. It was observed that levels of cross-reactive
neutralising antibodies are maintained over time, possibly
due to re-exposure [20]. Furthermore, individuals with
higher dengue NAb titres immediately after primary
infection had delayed symptomatic DENV infections
compared with children with lower titres. It has previ-
ously been suggested that the window of cross-protection
induced by a first infection with DENV against a second
symptomatic infection is approximately 2 years [21–23].
Although NAbs are correlated with protection against
symptomatic dengue, heterotypic secondary infection
(i.e., infection with DENV serotype different than the pri-
mary serotype) are more likely to result in severe disease
[24]. This is known as Antibody-Dependent Enhancement
(ADE). For instance, Katzelnick et al. showed that a
specific range of low-titre anti-DENV binding antibodies
were predictive of increased risk of severe dengue disease
in a Nicaraguan cohort study [25]. Such antibodies are
now been analysed following ZIKV infection in DENV-
immune and DENV-na€ıve individuals (L. Katzelnick, A.
Balmaseda, and E. Harris, unpublished data) to explore
whether preexisting anti DENV antibodies might also
enhance ZIKV. However, recent studies in non-human
primates and in humans do not support this hypothesis
Table 3 Percentage change of total number of severe dengue cases reported in 2017 compared to 2016, by countries and subregions
Country or Subregion
Epidemiological
week 2016 2017 Percentage change (%)
Central America Ithsmus and Mexico 1405 595 58
Costa Rica 52 21 0 100
El Salvador 52 206 7 97
Guatemala 52 47 64 36
Honduras 52 313 126 60
Mexico 52 806 375 53
Panama 51 12 21 75
Andean Subregion 1381 960 30
Bolivia 52 56 46 18
Colombia 52 1047 286 73
Ecuador 52 39 18 54
Peru 52 124 251 102
Venezuela 52 115 359 212
Southern Cone Subregion 909 378 58
Argentina 52 0 0 0
Brazil 52 861 378 56
Paraguay 52 48 0 100
Latin Caribbean Subregion 670 107 84
Cuba 52 29 19 34
Dominican Republic 52 641 88 86
Puerto Rico 52 0 0 0
The Americas 4368 2040 53
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[26, 27]. To better understand the existence and duration
of cross immunity for dengue and other flaviviruses, the
expert group concluded that future studies should
examine:
• Epidemiological effect of prior DENV infection on
Zika incidence and severity;
• Epidemiological effect of prior ZIKV infection on den-
gue incidence and severity;
• Immune correlates based on new-generation ELISA
assays: quality of antibodies in relation to clinical out-
come (cohort studies);
• Duration of antibodies in relation to interval of pro-
tection;
• Role of T-cells.
A distinction exists between cross-reaction and cross-
protection. It is well-established that cross-reaction does
not necessarily indicate cross-protection. There are a few
studies that postulate that cross-protection from Zika
occurs after a DENV infection [16, 18]. However, evi-
dently immunity resulting from DENV infection was not
sufficient to prevent the introduction and rapid spread of
Zika in the Americas. Nonetheless, prior DENV infection
and anti-DENV immunity is associated with protection
from symptomatic DENV infection, but not with protec-
tion against infection. Similarly, ZIKV immunity may
reduce symptomatic DENV infection [25]. However,
antibody depletion studies have shown that in DENV-
immune individuals, DENV cross-reactive antibodies do
not contribute significantly to ZIKV neutralisation [28].
Thus, the mechanisms of immunological cross-protection
are still not fully understood and the contribution of
CD8+ T cells responses has also been postulated [29, 30].
Based on the elements analysed, and based on a limited
number of studies, the group concluded that the hypothe-
sis of cross-immunity has the greatest weight in the
reduction of the incidence of dengue. To this are added
other elements such as an increase in vector interventions
during the period in question.
Hypothesis 3: Changes in the density and competencies
of vectors
During the past half century, there has been a rise in both
atmospheric concentration of carbon dioxide and average
world temperature. Climate change can produce extreme
meteorological conditions, heat waves, drought, food and
water contamination, and changes in vector distribution
(increase or decrease). During this time, emerging arbo-
virus disease patterns have changed significantly [31].
Due to increasing temperatures and precipitation through
warming oceans and extreme climatic variability,
problems with arthropod vectors, along with arboviruses,
will continue to emerge in new regions. This is illustrated
by the influence of climatic factors such as temperature
and humidity on dengue transmission and distribution.
Chandler found that only freezing temperatures kill eggs
and larvae of Aedes aegypti [32]. In contrast, rising tem-
peratures increases the length of the dengue transmission
season in temperate regions [33].
Temperature and humidity may also affect the beha-
viour, maturation and duration of infectivity in vectors.
Feeding behaviour is more frequent at higher tempera-
tures, which further affects transmission risk [34]. It may
also affect the initial time of mosquito infectivity. The
time between feeding and virus detection in the salivary
glands of Aedes aegypti decreased from 9 days at 26°C
and 28°C to 5 days at 30°C for DENV-1 and DENV-4
[35]. The expert group concluded that there is incomplete
knowledge to relate climate change to a decrease in den-
gue and unfortunately, few long-term studies regarding
predictions of climate change on vector-borne diseases.
Vector competence is the intrinsic ability of the vector
for infection, replication and transmission of a specific
virus. It begins with establishment of an infection fol-
lowed by replication in the epithelial cells. Afterwards,
the infecting agent traverses the midgut escape barrier
then replicates in other tissues. Finally, invasion and
infection of mosquito salivary glands followed by the
release in saliva transpires, resulting in the vector being
able to transmit the virus. According to Mitchell [36], a
species is considered a biological vector of arboviruses
when all the following facts occur:
• Virus is isolated from mosquitoes collected in nature;
• A mosquito is infected after artificial feeding using the
blood of a host in the viremic phase or a virus suspen-
sion;
• The virus can be transmitted to a host through a bite,
or detection of the virus in the a mosquito’s salivary
glands;
• Evidence in the field confirming an association
between a mosquito species and the population of ver-
tebrates in which the viral infection is occurring.
Several studies examining DENV in Aedes aegypti have
found high minimum infection rates (i.e., MIR = Number
of positive samples/total number of mosquitoes
tested 9 1000) for adult females [37, 38]. However, high
MIR rates in collected mosquito larvae indicate that ver-
tical transmission of DENV from an adult female to her
eggs may also occur [39].
Both Aedes aegypti and Aedes albopictus are able to
transmit dengue, Zika, chikungunya and even Yellow
Fever viruses with similar efficiency. Colder temperatures
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may however, decrease the local transmission of chikun-
gunya by European Aedes albopictus, possibly explaining
the lack of autochthonous transmission of the disease in
Europe despite hundreds of imported cases returning
from the Caribbean. Vega-Rua et al. found that expos-
ing European Aedes albopictus to lower temperatures
(20°C) significantly reduced CHIKV transmission
potential in the Asian genotype isolated from
Saint-Martin Island [40, 41].
The recent emergence of both chikungunya and Zika
viruses has increased the possibility that individuals may
become infected by more than one Aedes aegypti-borne
virus at a time. Recent clinical data support that Aedes
mosquitoes can be infected with and concurrently trans-
mit all three viruses [39].
Although the Aedes aegypti mosquito is susceptible to
climatic variables, elevated mosquito populations in the
Region continue, and within many areas, mosquito den-
sity remained at levels that maintain and support epi-
demics, suggesting that climatic factors did not result in
diminishing cases. Moreover, based on discussions after
literature review, the simultaneous circulation of three
arboviruses likely does not interfere in viral transmission
by mosquitoes [41, 42]. Nevertheless, evidence suggested
a recent intensification of vector control measures along
with new strategies, implemented (probably simultane-
ously) within several countries. Due to the arrival of
chikungunya followed by Zika, vector control units in
countries throughout the Americas intensified activities.
Among these, the Networking to Combat Zika and other
mosquito borne disease in the Caribbean, the Action Plan
for Prevention and control of the Zika virus in Central
America and the Dominican Republic, the National Plan
for Dengue, Chikungunya and Zika in Brazil and the
National Plan for Preparedness and Response to vector-
borne diseases in Colombia and Peru [43–45]. All these
countries had in common the following strategies: incor-
porating additional training for vector control technicians
and staff, reinforcement of the entomological surveillance
activities through larval surveys, vector control interven-
tions with the suppression of breeding sites using chemi-
cal and/or mechanical methods, use of insecticides to
reduce the adult mosquito population, community mobil-
isation and health education by strengthening communi-
cation activities related to personal measures of
prevention and protection and implementing integrated
plans or contingency plans for vector control and other
activities to improve entomological surveillance systems.
Several countries also implemented the use of pesticides
on a large scale, although the precise numbers are not
available. Overall, these interventions have previously
been demonstrated to reduce dengue incidence rates [46].
Furthermore, also apparent is greater and improved com-
munication both between and within countries. What is
unknown, however, is the impact of these measures on
the potential reduction in dengue burden and incidence.
Several suggestions to estimate this impact were provided
by the expert group, including:
• Intensify entomological surveillance and obtain infor-
mation regarding the presence of viruses in mosquitoes
in a more systematic way.
• Investigate the vector control intensification/improve-
ment practices within countries that resulted in mos-
quito density reductions. Despite many countries
reporting intensification of mosquito control activities,
specific details are not readily available. Obtaining this
information would assist other countries in following
similar protocols.
• Examine impact of the intensification/improvement of
vector control activities on dengue and other arboviral
disease incidence.
The expert group concluded that prior to implementing
vector control interventions, it is necessary to identify: (i)
where they are required and (ii) the surveillance data
needed to estimate their impact. Since vector control pro-
grams are evaluated using several variables (e.g., biologi-
cal, chemical, physical and personnel), improved data
collection, verification of variables producing an impact,
and identification of levels of intervention are essential.
Conclusions and next steps
A consensus was reached by the expert group that multi-
factorial explanations may account for the decline in den-
gue observed during 2017. Different elements were
described that might explain the reduction, including ele-
ments of immunity and increased vector control activities.
However, the degree of strength of these elements is
unknown. Mathematical modelling using retrospective
epidemiological information, along with existing
immunological and entomological data, could address
and quantify these uncertainties. In an epidemiological
model, one can try to estimate future forecasts of disease
incidence (by country or even by specific geographic
region). When new information is added, the model then
can be readjusted and subsequently becomes more accu-
rate. Increased availability of epidemiological models can
allow public health workers to identify and target high-
risk areas with appropriate and timely control measures.
Nevertheless, proper training in the use of these models is
necessary for cautious interpretation. Consequently, a
recommendation was set forth to create a working group
for mathematical space-time model development to
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estimate these effects and dynamics. Countries in atten-
dance were asked to provide weekly epidemiological data
during the past 10 years by state/province (i.e., first
geopolitical level of data). Specific data requested
included circulating serotypes, incidence of dengue, severe
dengue, and deaths stratified by gender and age group.
The expert group agreed that much uncertainty
remains regarding the sequence of infections between dif-
ferent types and ZIKV. To better understand the cellular
and functional properties of an acute DENV and ZIKV
infection and its role in cross-protection and
immunopathology, several proposals were recommended.
In DENV-1 followed by ZIKV infections, a subset of B
cells generated cross-neutralising antibodies [47]; a simi-
lar relation has been observed for DENV-3 and ZIKV (P.
Andrade and E. Harris, unpublished data). The basis for
this observation is not known; therefore, further studies
are needed. Additionally, several cohort studies exist per-
taining to the behaviour of antibodies after an arboviral
infection. To better analyse this behaviour, systematic
reviews and meta-analyses of existing cohort studies are
recommended.
Case–control studies stratified by previous immune sta-
tus were also suggested. Two sets of case–controls were
proposed: individuals with a laboratory confirmation of
dengue (cases) vs. healthy persons (controls) and severe
(cases) vs. non-severe (controls) dengue. Through labora-
tory tests, there is a need to demonstrate: cross-immunity
between dengue and Zika viruses that this cross-immu-
nity between the two viruses is protective, that this possi-
ble protection could result in a large reduction in dengue
incidence and undertake follow-up studies to document
the duration of this protective effect once demonstrated.
Changes in mosquito density and competence may
have played a role in the reduction in dengue throughout
the Americas due to intensification of vector control
activities. Whether specific vector control elements were
performed with quality, time, place, and simultaneously
with other coinciding control actions in a manner that
impacted and reduced infection and stopped local epi-
demics or reduced transmission is unknown. Follow-up
research studies should investigate the question of
whether increased vector control intensification and/or a
combination of activities contributed to the decline in
transmission of arboviruses. Proposed studies should
focus on whether enhanced entomological surveillance
has an impact on incidence of arboviruses with a goal of
applying specific measures that mitigate seasonal occur-
rence or an outbreak. Examples of studies proposed by
the expert group include:
• Determine whether the population of mosquitoes at a
local level was infected and infectious by conducting a
prospective study examining the infectivity of mosqui-
toes by various types of arboviruses.
• Conduct cross-sectional studies to examine which
mosquitoes are currently transmitting DENV, via data
obtained from the country entomological surveillance
system.
• Conduct research to assess whether Cx. quinquefascia-
tus plays a role in ZIKV transmission, as some studies
suggest this possibility [41].
• Develop cross-sectional evaluations comparing vector
control interventions to define which entomological
indicators are best assessed and measured over time.
We used the expert consensus methodology in this
study considering that it is a valuable approach when
other evidence is unavailable and is considered adequate
to validate hierarchies of evidence. The number of panel
members in our study was higher than the recommended
8–12 members for a consensus panel [48]. We increased
this number to constitute a multidisciplinary group and
obtain a wider range of opinions as has been suggested in
previous reports [49].
However, the method was subject to limitations such
as potential for bias in the selection of participants, the
possibility of having been a random variation in panel
behaviour and not ranking the feedback of the experts to
weight their agreement using a scale. We consider that
we have included experts with considerable experience
and a thorough knowledge of the study topic from acade-
mia, and government institutions who contributed
equally to the product of the study. As has been cited in
other reports, this method has acceptable construct valid-
ity [50] and reliability [51]. It is important to mention
that unless the findings can be tested against observed
data, we can never be sure that the methods have pro-
duced the correct answer.
In conclusion, using the expert group, it was agreed
that the decrease in dengue cases in the Americas has
been evidenced by the epidemiological surveillance sys-
tems of the countries of the countries of the Americas.
This decrease initiated after two major epidemics;
Chikungunya (2013) and Zika (2015). Among the
hypotheses reviewed that may explain this unprecedented
phenomenon, the working group concluded that the
greatest weight is the existence of cross-immunity
between Zika and Dengue. This hypothesis establishes
that patients with a history of dengue infection who are
subsequently infected with Zika have protective immunity
against a new dengue infection. Another important
hypothesis that cannot be ruled out is the increase and
strengthening of vector control interventions which
included an important community response in combating
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the vector through the elimination of breeding sites.
These vector control actions were characterised by a sig-
nificant dissemination of information campaigns for the
general public through various means. Nevertheless, a
recent publication reviewed possible causes of the decline
of dengue in Brazil considering herd immunity, cross-
reactivity between Zika and Dengue, vector control mea-
sures and environmental factors and concludes that these
are not sufficient to explain the dengue scenario in Brazil
in 2017 [52]. There is a need to provide additional evi-
dence concerning the immune response and protection to
new infections in the community as well as information
on the duration of the acquired immunity. Finally, it is
necessary to better understand the impact of vector con-
trol actions on the transmission of arboviruses. For this,
the development of new scientific research is decisive
now and before the current transmission pattern changes.
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